We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Paramount+ offers exclusive live streams and on-demand replays of all UEFA Champions League matches and when you sign up, you ...

The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...

There has also been an increase in research examining other benefits these types of drugs might offer aside from type 2 ...

The FDA is expected to decide on treatments for familial chylomicronemia syndrome, type 1 diabetes, short bowel syndrome, and Prader-Willi syndrome.

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Fewer patients experienced a first hospital admission for any indication and for serious adverse events while on semaglutide.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...